WAY 316606 Powder
|Other Names||WAY 316606, WAY-316606, CHEMBL495575, CS-0996, GTPL9945, SCHEMBL4618018, DTXSID90587395|
|Purity||≥99% Pure (LC-MS)|
|Powder Availability||5 grams|
|Storage||Store in cool dry environment, away from direct sunlight.|
|Terms||All products are for laboratory developmental research USE ONLY. Products are not for human consumption.|
Background of WAY-316606
WAY-316606 is a potential new treatment for hair loss. It is an inhibitor of the protein sFRP-1. sFRP-1 acts as a modulator of Wnt pathways. The Wnt pathways play a large role in the transcriptions of genes which then leads to how the genes are expressed. Cell differentiation typically occurs in the dermal papillae (DP) near the base of the hair follicle. During this period of growth, proteins such as sFRP-1 are produced throughout the protein. Overexpression of sFRP-1 during this phase can lead to structural defects in the hair strand.
Since the Wnt pathway plays an important role in cell determination, researchers have begun to examine what long lasting effects exist when the Wnt pathway is blocked by sFRP-1. One of the primary concerns is that with the Wnt pathway inhibited, it will not be able to modulate the activity of the protein 𝛃-catenin, specifically in the hair follicle bulbs. In order to determine the magnitude of the inhibitory effects Wnt signaling has on 𝛃-catenin, researchers Hawkshaw et. Al treated a hair follicle for 48 hours with an inhibitor of Wnt production-2 (IWP-2). By treating the follicle with IWP-2, there was a drastic decrease in the transcription of axis inhibition protein 2 (AXIN2) and lymphoid enhancer binding factor 1 (LEF1), both of which promote the canonical activation of 𝛃-catenin. This indicates that Wnt pathway signaling is an important factor of 𝛃-catenin activation in the hair follicle.
Examining the Efficacy of WAY-316606
The proper functioning of sFRP-1, the Wnt pathways, and 𝛃-catenin are important when examining the efficacy of treating hair follicle dysfunction with WAY-316606. The findings of the first initial study found that the Wnt pathways are crucial to proper activation of 𝛃-catenin. Since sFRP-1 is an inhibitor of the Wnt pathways, the research team came to the conclusion that sFRP-1 inhibits 𝛃-catenin activity.
This conclusion led to a follow up study examining various treatment methods to combat the downregulation of 𝛃-catenin. Hair follicles were incubated with WAY-316606, a potent inhibitor of sFRP-1, over the course of 48 hours. After the test period it was found that transcription of LEF1 and AXIN2 were dramatically increased. This result further solidifies the finding of the initial trial mentioned above. When sFRP-1 is not inhibited by WAY-316606 there a decrease in 𝛃-catenin activity (indicated by LEF1 and AXIN2 levels), but when sFRP-1 is inhibited by WAY-316606, there is an increase in 𝛃-catenin activity in the hair follicle. Proper activation of 𝛃-catenin is important to hair growth due to the differentiation of keratinocytes as well as the anagen-inducing properties of the dermal papillae.
WAY-316606 was further tested to determine its effects on keratin expression. The findings of this study were measured through the use of immunohistomorphometry and the quantitative results determined that treatment with WAY-316606 significantly increased the protein expression of the hair shaft keratin. Additionally, WAY-316606 was tested to see its overall effect on hair growth. Hair follicles were treated with WAY-316606 and hair shaft production was precisely measured over the course of a 6 day treatment period. The research found that treating the follicle with WAY-316606 caused an increase in hair shaft production as early as two days into the treatment period. The efficacy of WAY-316606 was compared to that of the previously established sFRP-1 inhibitor Cyclosporine A (CsA). All of the findings of the studies regarding WAY-316606 indicated that it is vastly more effective in its production of the hair shaft than CsA.
Researchers Hawkshaw et. Al continued their comparison of WAY-316606 to CsA by determining each compound’s ability to prolong the duration of anagen, which is an essential part to managing hair loss. CsA achieves this by blocking catagen, but it was unknown if WAY-316606 was capable of mimicking these effects. After a 6 day treatment period tracked through histomorphometry, it was found that there was a higher percentage of IV anagen in the hair follicles. This corresponded to a greater percentage of circulating keratinocytes, a higher number of DAPI+ cells, and higher melanin content as well as a reduction in emigrating fibroblasts from the dermal papillae. These results mirror the action of CsA almost exactly, indicating that the inhibition of sFRP1 through the administration of WAY-316606, leads to high rates of hair shaft production and the maintenance of anagen in the hair follicle, both of which are extremely important to combating hair loss (https://journals.plos.org/plosbiology/article?id=10.1371/journal.pbio.2003705).
The nootropics sold by Umbrella Labs are sold for laboratory research only. The description above is not medical advice and is for informative purposes only.
WAY 316606 is sold for laboratory research use only. Terms of sale apply. Not for human consumption, nor medical, veterinary, or household uses. Please familiarize yourself with our Terms & Conditions prior to ordering.